Table 2 Details of efficacy calculations

Reduction in the probability of HPV infection

Assumed proportion of HPV 16/18 in cervical cancer, A

74.9%

74.9%

[7]

Vaccine efficacy-percent reduction in HPV 16/18 persistent infections, B

95.0%

95.0%

[23, 27, 28, 32–40]

Assumed proportion of other high risk HPV in cervical cancer, C

23.4%

23.4%

[7]

Vaccine efficacy-percent reduction in other high risk HPV persistent infections, D

68.4%

32.5%

[30–32]

Calculated reduction in the probability of HPV infection (AxB)+(CxD)

87.2%

78.8%

Corection factor for CIN1

Percent of HPV 1618 in CIN1 cases which are caused by oncogenic HPV, E

37.0%

Correction factor for CIN1, A-E

37.9%

Corection factor for CIN2/3

Percent of HPV 1618 in CIN2/3 cases which are caused by oncogenic HPV, F

52.0%

Correction factor for CIN2/3 A-F

22.9%